Cardiff Oncology is a clinical-stage biotechnology company developing novel oncology therapies by leveraging PLK1 inhibition. Its lead drug candidate, onvansertib, is an oral, highly selective PLK1 inhibitor with a 24-hour half-life, designed to be used in combination with standard-of-care therapeutics to target tumor vulnerabilities and overcome treatment resistance. The company's clinical programs focus on indications with significant unmet medical need, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and chronic myelomonocytic leukemia. Key ongoing trials include the Phase 2 CRDF-004 study in first-line RAS-mutated metastatic colorectal cancer, conducted in partnership with Pfizer Ignite, and investigator-initiated trials at institutions such as the University of Kansas Medical Center, University of Maryland, Baltimore, and Dana-Farber Cancer Institute. The development strategy incorporates tumor genomics and biomarker assays to refine patient selection and assess treatment response.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage cardiffoncology.com
Sector Healthcare IR page investors.cardiffoncology.com/static-files/b953b5d3-6858-417a-b165-da75674ecf9f%20
Tags
oncology, plk1 inhibition, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, leukemia, small molecule, combination therapy, clinical-stage, onvansertib, CRDF-004, CRDF-005, Pfizer Ignite, FOLFIRI, FOLFOX, bevacizumab, NALIRIFOX, Gemzar, Abraxane, paclitaxel, irinotecan, 5-fluorouracil, abiraterone, venetoclax
Press page —

Metrics

Valuation  
Market cap $ 94.132M
Market cap (USD) $ 94.132M
P/E -2.20
PEG —
P/BV 3.35
P/S 168.39
P/OCF -2.36
P/FCF -2.48
Dividend yield —
Turnover / mcap —
Returns  
ROE -71.5%
ROI -163.6%
ROIC -131.0%
Profit margin -7,732.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score -82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Revenue 593K 683K 488K 386K 359K 365.993K 244.632K 378.325K 505.404K 381.072K 312.812K 280.178K 259.246K 450.404K 257.696K
Net profit -45.851M -45.431M -41.441M -38.704M -28.291M -19.307M -16.414M -16.461M -24.907M -39.204M -27.471M -14.325M -11.811M -11.566M -2.239M
Free cash flow -37.967M -37.773M -31.469M -34.826M -23.245M -16.527M -13.335M -13.204M -23.382M -31.863M -24.36M -13.091M -7.967M -5.205M -1.932M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Share price 2.81 4.34 1.48 1.4 6.01 17.99 1.24 — — — — — — — —
Price performance 12m -0.35 1.93 0.06 -0.77 -0.67 13.51 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 100,460 77,095 167,755 203,480 320,458 535,000 771,000 288,000 773,000 182,000
↳ YoY growth +1.7% -23.3% +117.6% +21.3% +57.5% +66.9% +44.1% -62.6% +168.4% -76.5%
↳ 5y CAGR +0.3% -14.5% +16.3% +29.1% +26.5% +39.7% +58.5% +11.4% +30.6% -10.7%
Borrowings, current (USD) 2.36M 1.33M 0.00 — — — — — — —
Borrowings, non-current (USD) 14.2M 0.00 — — — — — — — —
Lease liabilities (USD) — — 0.00 1.73M 869,497 3.12M 2.72M 2.15M 1.52M 832,000
Cash and deposits (USD) 13.9M 8.23M 11.5M 10.2M 131M 11.9M 16.3M 21.7M 51.5M 17.5M
Right-of-use assets (USD) — — 0.00 697,418 343,001 2.8M 2.25M 1.71M 1.17M 629,000
Net debt (borrowings + leases - cash) (USD) 2.62M -6.89M -11.5M — — — — — — —
Cash flow detail
Operating cash flow (USD) -31M -23.3M -13.2M -13.3M -16.3M -23M -33.8M -30.9M -37.7M -37.9M
Purchases of property, plant and equipment (USD) -823,483 -101,101 -5,100 -67,622 -211,880 -205,000 -1.01M -582,000 -80,000 -44,000
Change in receivables (cash effect) (USD) -1,724 23,365 19,262 -35,725 -116,978 -215,000 -236,000 483,000 -484,000 591,000
Change in payables (cash effect) (USD) 2.16M -2.94M 236,484 1.46M 1.28M 719,000 1.35M 2.83M 2.99M 2.2M
Interest paid (cash effect) (USD) -1.1M -668,465 -22,482 0.00 — — — — — —
Income taxes paid (cash effect) (USD) -4,560 -800 -800 -800 -800 -1,000 -2,000 -1,000 -1,000 -1,000
Share-based compensation (USD) 7.5M 4.01M 2.17M 884,943 1.76M 3.23M 4.26M 4.51M 4.76M 5.69M
Operating cash flow before change in receivables (USD) -31M -23.3M -13.2M -13.2M -16.2M -22.8M -33.6M -31.4M -37.2M -38.5M
Free cash flow (OCF - PPE - intangibles) (USD) -31.9M -23.4M -13.2M -13.3M -16.5M -23.2M -34.8M -31.5M -37.8M -38M
Income detail
Research and development expense (USD) 15M 7.88M 8.16M 11.2M 11.2M 17.4M 27.1M 32.9M 36.9M 35.3M
↳ 5y CAGR +75.1% +32.6% +15.6% +10.9% +1.2% +3.0% +28.0% +32.1% +27.0% +25.8%
Total comprehensive income (USD) -39.2M -24.9M -19.3M — -19.3M -28.4M -39M -41.1M -45.3M -45.8M
Comprehensive income to owners (USD) -39.2M -24.9M -19.3M — -19.3M -28.4M -39M -41.1M -45.3M -45.8M
Reported Feb 26, 2018 Feb 26, 2018 May 7, 2019 Feb 27, 2020 Feb 24, 2022 Feb 24, 2022 Mar 2, 2023 Feb 29, 2024 Feb 24, 2026 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have now exceeded 21 months on treatment

Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027

SAN DIEGO, Calif., November 12, 2026 — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Building on the strength of these data, we are actively preparing for our upcoming registrational trial.

November 3, 2026

PDF Version

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.

Details of the presentation can be found below.

**Format:**Fireside Chat Presenter: Mani Mohindru, PhD (President and CEO) Date: November 16, 2026 **Time:**2:40 PM GMT

Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff****Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

October 27, 2026

PDF Version

Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies

SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs. Dr. Alland succeeds Roger Sidhu, MD, who has stepped down from his role as Chief Medical Officer.

“We are pleased to welcome Leila as interim Chief Medical Officer,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “She brings a strong track record of leadership in advancing novel cancer therapies and is well-positioned to guide our clinical strategy as we enter a pivotal phase in clinical development. Our randomized Phase 2 trial in first line RAS-mutated metastatic colorectal cancer is still ongoing, and median PFS has not been reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm, our proposed Phase 3 regimen. All patients remaining on trial have now been on treatment for more than 18 months. We are at a defining period for Cardiff as we prepare to initiate our registrational Phase 3 study in the first quarter of 2027. Leila’s expertise will be instrumental as we advance this program and also evaluate the broader potential of PLK1 inhibition in other cancers with few treatment options.”

“Despite advances in the treatment of metastatic colorectal cancer, significant unmet needs remain, particularly for patients with RAS-mutated disease,” said Dr. Alland. “I believe onvansertib's differentiated approach, which targets a key vulnerability of RAS-mutated tumors through PLK1 inhibition, holds significant promise for addressing these challenges and improving patient outcomes. I am excited to take on this role at such an important stage in its development and help translate that promise into meaningful clinical benefit for patients.”

Dr. Alland has served as Chief Medical Officer at several clinical-stage biotechnology companies, including PMV Pharma, a precision oncology company focused on p53; Affimed, an immuno-oncology company; and Tarveda Therapeutics, a company developing targeted drug conjugates. Previously, she held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approvals of oncology therapies including Tagrisso®, Opdivo®, Tasigna® and Caelyx®. Dr. Alland currently serves on the Board of Directors of Abeona Therapeutics Inc.

Dr. Alland received her medical degree from New York University and her bachelor's degree from the University of Pennsylvania. She completed her pediatric training at The Children's Hospital of Philadelphia and her hematology/oncology training at Memorial Sloan Kettering Cancer Center. She previously served on the faculty of Albert Einstein College of Medicine, where she cared for children with cancer and conducted research focused on oncoproteins and epigenetics.

Opdivo® is a registered trademark of Bristol-Myers Squibb Company. Tagrisso® is a registered trademark of AstraZeneca PLC. Tasigna® is a registered trademark of Novartis AG. Caelyx® is a registered trademark of Johnson & Johnson.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

Prompts

Cardiff Oncology, Inc. (ticker CRDF), listed in United States.

Company History

Date Change Detail
May 13, 2020 Renamed TROVAGENE, INC. → CARDIFF ONCOLOGY, INC.
Nov 25, 2011 Renamed XENOMICS INC → TROVAGENE INC.
Jul 19, 2004 Renamed USED KAR PARTS INC → XENOMICS INC